Experts Forecast Cancer Research and Treatment Advances in 2020

Around 400 BC, the Greek physician Hippocrates is believed to have first described tumors as “cancer,” using the words “karkinos” or “karkinoma,” which stem from the Greek word for “crab”. Today, hundreds of different types of cancer have been described. As our understanding of this group of diseases continues to grow, cancer prevention, detection, and treatment advancements continue to evolve.

Read More

FDA Approves New Treatment for HER2-positive Breast Cancer

The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating certain patients with breast cancer on Dec. 20, 2019. Specifically, it was approved for treating adults who have unresectable or metastatic HER2-positive breast cancer that has progressed despite treatment with two or more other HER2-targeted treatment regimens after the diagnosis of metastatic disease.

Read More

2019 in Review: Progress Across Many Areas of Cancer Research

In 2019, research continued to drive progress across the spectrum of cancer care in the form of new and better ways to prevent, detect, diagnose, and treat some of the many diseases we call cancer. Here’s a look at some key developments in drug approvals, immunotherapy, precision medicine, and disparities research.

Read More

New AACR-Novocure Funding Initiatives Support Tumor Treating Fields Research

Earlier this year, the American Association of Cancer Research (AACR) partnered with Novocure, a global oncology company, to launch several new funding initiatives to support innovative research focused on Tumor Treating Fields (TTFields). TTFields is a novel noninvasive cancer therapy approved by the U.S. Food and Drug Administration for the treatment of adults with glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Patients wear a portable electric field generator that delivers TTFields to tumors via electrodes attached to the skin over the tumor site.

Read More

AACR Journals Editors’ Picks for October

As October comes to a close, it’s time for our latest edition of Editors’ Picks. This monthly staple is a collection of 10 “must read” articles that have been hand-selected by the editors from the portfolio of journals published by the AACR. This month, featured articles include results from three clinical trials and a look at cancer disparities among American Indians and Alaska Natives, among others. As always, articles highlighted here are freely available for a limited time.

Read More

A Look at Liver Cancer

As Greek mythology tells us, the titan Prometheus was punished by the gods for giving fire to man. His sentence? Eternal torture. Each day, an eagle would eat his liver, which would grow back overnight, ready to be devoured by the eagle again the next day.

The liver’s ability to regenerate presumably evolved to protect it from damage from food toxins. However, chronic cycles of liver damage and regeneration can lead to aberrant replication and eventually the development of liver cancer.

Read More

Bringing Awareness to Breast Cancer in October

Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United States, it is estimated that over 40,000 women and roughly 500 men will die from breast cancer in 2019. Despite progress in developing new treatment modalities for patients with this disease, there is still substantial work to be done in the field.

Read More

Frontiers in Cancer Science: the Singapore Cancer Conference

Providing a forum for innovative cancer researchers around the world, Singapore will hold its 11th Frontiers in Cancer Science (FCS) conference from November 4-6 at Academia at SingHealth.

The conference is jointly organized by the Cancer Science Institute of Singapore, Duke-NUS Medical School, Genome Institute of Singapore, Institute of Molecular and Cell Biology, Lee Kong Chian School of Medicine, National Cancer Centre Singapore, and National University Cancer Institute, Singapore.

Read More

AACR Meeting Highlights Recent Advances in Pediatric Cancer Research

Pediatric cancer, while rare, is a devastating diagnosis that is estimated to affect over 11,000 children in the United States in 2019. Among those diagnosed between birth and age 14, more than 1,000 are anticipated to die from the disease this year. The most common types of cancer in this age group are leukemias, brain and other central nervous system (CNS) tumors, and lymphomas.

Read More